Witty’s Bonus Slashed As GSK Recovers From China Scandal
This article was originally published in PharmAsia News
Executive Summary
Still learning lessons from 2013's bribery scandal and subsequent investigations in China, GlaxoSmithKline's CEO Sir Andrew Witty had his annual bonus for the past year slashed in half.